NLNK-20130930-8K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2013 (September 30, 2013)



NewLink Genetics Corporation
(Exact name of registrant as specified in its charter)

Delaware	001-35342	42-1491350
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


2503 South Loop Drive Ames, IA		50010
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (515) 296-5555

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 - Other Events

Item 8.01. Other Events.

On September 30, 2013, NewLink Genetics (NASDAQ:NLNK) announced the presentation of data on its lead HyperAcute cancer immunotherapy product candidates at the 2013 European Cancer Congress (ESMO) in Amsterdam, The Netherlands.

The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit Number		Description
99.1		Press Release, dated September 30, 2013, entitled “NewLink Genetics Presents Data Demonstrating Potential Chemo-Sensitization Activity of its HyperAcute^TM Cancer Immunotherapy Product Candidates”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 30, 2013



	NewLink Genetics Corporation


By:	/s/ Gordon H. Link, Jr.
	Gordon H. Link, Jr.
Its:	Chief Financial Officer

INDEX TO EXHIBITS



Exhibit Number		Description
99.1		Press Release, dated September 30, 2013, entitled “NewLink Genetics Presents Data Demonstrating Potential Chemo-Sensitization Activity of its HyperAcute^TM Cancer Immunotherapy Product Candidates”